News
Why the TAAR1 Agonist Ulotaront Holds Promise for Schizophrenia
November 22, 2022 · By Brian Buntz · Drug Discovery & Development
News
4 Next-Gen CNS Drug Development Trends
By Brian Buntz · October 24, 2022 · Drug Discovery & Development
News
Why Psychogenics and Emyria are Collaborating to Examine MDMA-Inspired Compounds
By Brian Buntz · Oct 12, 2022 · Drug Discovery & Development CNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage...
News
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Oct 11, 2022 · Business Wire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and...
News
Emyria Starts Program with Neuroscience Drug Discovery CRO
By Jim Cornall · Sept 22, 2022 · Labiotech.eu Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics,...